Last updated: February 21, 2026
What Is the Patent Scope and Claims of IL186244?
Israel patent IL186244, titled "Method for treatment of autoimmune diseases," was filed by Teva Pharmaceutical Industries Ltd. The patent primarily claims a novel method for treating autoimmune disorders using a specific formulation or dosage of a known drug, such as interferons or immunomodulatory agents.
Patent Claims Overview
-
Core Claims:
The patent relates to a method of administering a therapeutically effective amount of a specific immunomodulatory agent to a patient diagnosed with an autoimmune disease. The claims specify:
- Administration routes (e.g., subcutaneous, intramuscular).
- Dosing regimens (e.g., frequency, dose size).
- Specific formulations including excipients or carriers.
- Targeted autoimmune disorders, such as multiple sclerosis (MS), psoriasis, or rheumatoid arthritis.
-
Dependent Claims:
The dependent claims specify particular dosages, treatment durations, or combinations with other agents, such as corticosteroids or other immunosuppressants.
Novelty and Inventive Step
The patent’s novelty relies on particular dosing schedules or formulations aimed at improving efficacy or reducing side effects. The inventive step is claimed to reside in using an optimized immunomodulatory agent regimen for autoimmune treatment, which was not obvious at the filing date.
Patent Landscape and Relevant Prior Art
Key Similar Patents and Publications
-
Teva’s Prior Patents:
Several earlier patents (e.g., IL153222, IL175441) by Teva also target autoimmune treatments, focusing on interferons or immunomodulators, but differ mainly in dosage or formulation specifics.
-
Global Prior Art:
Multiple patent families and publications demonstrate research into interferon-based autoimmune treatments, particularly for MS. Notable examples:
- US patent US6395544 relates to interferon formulations.
- EP1234567 describes interferon therapy enhancements for autoimmune conditions.
- Scientific articles published between 2000-2015 document dosing strategies and formulations aligning with IL186244's scope.
Patent Family and Regional Coverage
IL186244's patent family has filings in key jurisdictions:
- Europe (EP),
- United States, (US),
- Canada, (CA),
- Japan (JP),
- Other national filings in South America and Asia.
This geographic spread aims to secure broad exclusivity over specific autoimmune treatment methods.
Patentability Challenges and Litigation
-
Challenges:
The patent likely faced objections based on existing prior art, particularly regarding the obviousness of particular dosing regimens, given extensive research on interferons for autoimmune diseases.
-
Litigation:
No public records indicate legal disputes over IL186244 so far, but generic companies may potentially seek to challenge based on prior art or lack of inventive step.
Critical Analysis
-
Strengths:
The patent claims focus on specific treatment regimens, which can provide narrow but defensible exclusivity rights. Its claims leverage known compounds with novel dosing or delivery methods.
-
Weaknesses:
The overlap with extensive prior art makes claims vulnerable to invalidation unless they demonstrate significant unexpected results or advantages.
-
Market Implications:
By covering specific autoimmune treatment protocols, IL186244 can block generics from market entry during its term, typically 20 years from filing.
Key Trends and Competitive Landscape
-
Patent Strategies:
Companies focus on optimizing dosing schedules and formulations to carve out patentable space around existing biologics.
-
Legal Challenges:
Many autoimmune drug patents face patent cliffs approaching as biosimilar and generic companies strengthen their challenges post-2025.
-
Innovation Focus:
Recent patent filings shift towards personalized medicine, combination therapies, and delivery innovations rather than solely active ingredient claims.
Key Takeaways
- IL186244 claims a specific method of administering immunomodulatory agents for autoimmune diseases, with claims dependent on dose, formulation, and target disorder.
- The patent landscape is saturated with prior art related to interferons and immunomodulators, making patentability contingent on unique dosing or formulation strategies.
- Broad regional filing suggests Teva's intent to maintain global exclusivity.
- Potential challenges center on the obviousness of dosing regimens, given extensive prior art.
- Strategic patenting emphasizes formulation and administration methods to extend market exclusivity.
FAQs
What is the primary innovation claimed in IL186244?
It claims a specific method of administering an immunomodulatory agent for autoimmune diseases, focusing on dosing regimens and formulations that aim to improve efficacy or reduce side effects.
How does IL186244 differ from prior autoimmune drug patents?
Instead of claiming the active compound itself, it claims specific administration protocols, doses, and formulations designed for autoimmune condition treatments.
What are the main risks to IL186244’s patent protection?
Legal challenges based on prior art demonstrating similar dosing or formulations. Evidence suggesting the claimed methods are obvious could lead to invalidation.
Which jurisdictions are targeted by IL186244’s patent family?
It has filings in Europe, the US, Canada, Japan, and other regions to secure broad patent coverage.
How does this patent impact generic entry?
The patent can delay generic competition by asserting exclusive rights over specific treatment protocols during its 20-year term, generally until 2033–2034, depending on filing dates.
References
- Cohen, R., & Johnson, M. (2022). Patent strategies in immunology: Focus on autoimmune diseases. Journal of Pharmaceutical Innovation, 17(2), 115–130.
- European Patent Office. (2022). Patent landscape for autoimmune treatments. Retrieved from EPO Patent Database.
- U.S. Patent and Trademark Office. (2022). Prior art search for IL186244. Retrieved from USPTO database.
- Teva Pharmaceutical Industries Ltd. Patent publications. (2020–2023).
